🇺🇸 iMAB in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 1
Most-reported reactions
- Atypical Fracture — 1 report (100%)
Other Oncology approved in United States
Frequently asked questions
Is iMAB approved in United States?
iMAB does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for iMAB in United States?
European Organisation for Research and Treatment of Cancer - EORTC is the originator. The local marketing authorisation holder may differ — check the official source linked above.